AZTR (Azitra) Short Percentage of Float


AZTR Azitra Inc AZTR
35 GF Score
Price $0.17
! 1 Warning Sign
View Full Analysis

What is Azitra Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AZTR vs CASIF, ITRMF, OGEN: Short Percentage of Float Comparison

For the Biotechnology subindustry, Azitra's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azitra Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Azitra's Short Percentage of Float falls into.


AZTR
35GF Score
Azitra Inc AZTR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Azitra Business Description

Address 21 Business Park Drive, Branford, CT, USA, 06405
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
35GF Score

Get the complete analysis for AZTR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price